Lakshmi Rajdev

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison et al. · Journal of Clinical Oncology · 2015 · 524 citations

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Qian Shi, Jennifer J. Knox et al. · JAMA Oncology · 2019 · 114 citations · Full text

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

Ghassan K. Abou‐Alfa, Donna Niedzwieski, Jennifer J. Knox et al. · Journal of Clinical Oncology · 2016 · 103 citations

Pathology, Doxorubicin Versus Sorafenib, Pharmacotherapy +20

PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Arjun B. Sood, Danielle McClain, Radhashree Maitra et al. · Clinical Colorectal Cancer · 2012 · 97 citations

Medicine, Pten Gene Expression, Immunology +6

Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer

Joseph A. Sparano, Umekalsoom Malik, Lakshmi Rajdev et al. · Journal of Clinical Oncology · 2001 · 81 citations